Navigation Links
Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
Date:5/30/2008

SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102 Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare, and Chief Scientific Officer of US Oncology.

A live audio-only Webcast of this presentation can be accessed beginning at 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektar website: http://www.nektar.com/wt/page/asco. A replay will also be accessible through the same link through June 15, 2008.

To attend this event in person, please RSVP no later than Sunday, June 1, 2008 to Vanessa Rivas: vrivas@nektar.com.

Time: 6:00 - 6:30 PM (Central Time) -- Registration

6:30 PM (Central Time) -- Webcast presentation

Location: Fulton's on the River

Riverfront Room and Veranda

315 N. LaSalle Street

Chicago, IL 60610

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation technology has enabled eight approved products for partners, which include leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

Contact: Jennifer Ruddock, +1-650-283-6253, jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
6. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
7. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
8. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
9. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
10. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... December 02, 2019 , ... Smile Brands Inc., one ... the United States, today announced the grand opening of another affiliated Bright ... will enjoy convenient hours, a comfortable office and full-service care at the new ...
(Date:12/2/2019)... ... 2019 , ... Strong public health departments engaged in effective ... Striving to fulfill their crucial mission, more and more health departments are placing ... Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial five-year accreditation ...
(Date:11/30/2019)... ... November 28, 2019 , ... Craig Wallentine, ... elected chairman of the board of trustees of the International Safety Equipment ... President & CEO, Ergodyne , was elected vice chairman. , Nate Kogler, ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 06, 2019 , ... C&A Industries , a national ... The Omaha-based company has been named by Training magazine to the Training ... development programs worldwide. Rankings of the 125 leading companies will be announced on ...
(Date:12/6/2019)... , ... December 06, 2019 , ... Allegheny Health Network ... Dr. Gyure, who joined AHN from WVU Medicine in May 2018, previously served as ... has served as interim chair since October and is also part of the pathology ...
(Date:12/6/2019)... ... 06, 2019 , ... TIME For Kids (TFK) revealed the first-ever ... innovative, and fun destinations that are tailored to the interests of kids. The list ... To assemble the list, TIME for Kids gathered nominations from its network of ...
(Date:12/5/2019)... , ... December 05, 2019 , ... ... M&A: Risks and Rewards of Building Platforms— on Thursday, December 12, 2019, at ... for large, multi-specialty medical groups. Middle-market PE firms are scrambling to assemble regional ...
(Date:12/4/2019)... ... , ... A November 12 article on NBC Connecticut reported on ... The article highlighted the life-changing or life-ending consequences of some E-scooter accidents, from a ... fatality after an incident with a vehicle. Los Angeles-based personal injury law firm Legal ...
Breaking Medicine News(10 mins):